Blood Panel Detects Liver Cancer With High Accuracy
A six-marker biomarker test distinguishes hepatocellular carcinoma from chronic liver disease, though prospective validation is still required.
Updated on Nov. 6, 2026 in Cancer
Researchers developed a blood-based panel combining DNA methylation and protein markers to distinguish hepatocellular carcinoma from chronic liver disease. The model was developed in populations predominantly affected by hepatitis B virus.
Why it matters
Hepatocellular carcinoma is often diagnosed late, and a reliable blood test could help identify it earlier in people with chronic liver disease. The panel's performance so far comes from case-control studies, so its real-world clinical value remains to be confirmed.
In an independent cohort of 149 participants, the model reached 88.4% sensitivity and 93.8% specificity, with 82.9% sensitivity for early-stage (BCLC 0-A) tumors. These are case-control results, and prospective studies have not yet confirmed them.
The details
The model combines four DNA methylation markers with two protein markers, built from genome-wide methylation profiling of 55 liver cancer tissues and matched non-cancer tissues, then assessed alongside five protein markers in 299 blood samples. It was then tested in an independent cohort of 149 participants.
Health Landscape
Alpha-fetoprotein has long been the standard blood marker for liver cancer surveillance, but it misses many early tumors. This six-marker panel is tested against AFP and des-gamma-carboxyprothrombin, and it outperformed both in this case-control setting.
If prospective studies confirm these results, blood-based screening could complement imaging for people with chronic hepatitis B or liver disease. Readers should discuss liver surveillance options with their clinicians, as this test is not yet available for routine use.
The takeaway
Early detection of liver cancer depends on tests that catch tumors before they progress. This research points toward combining molecular markers, but prospective validation will determine whether it changes outcomes.
Further reading
Explore more on Cancer research and detection advances.
